Joseph Krueger BS, PhD

Joseph is Advances in tissue biomarker quantification and tissue context localization have led to great achievements in understanding cancer biology, and can help us intelligently develop personalized therapeutics. His Successful approaches to personalized medicine have focused on gene mutations and amplifications as innate tumor drivers, but the recent breakthroughs in immuno-oncology have demonstrated that the adaptive interaction of the tumor with the microenvironment is as much a determining factor in response to therapy.
In addition to innate attributes described by genomic approaches, each patient’s tumor has unique and highly complex associations between cells within the tumor tissue that embody the key driving biology of the disease. Even more so, there appears to be a direct, functional relationship between the innate genomic attributes and immune response. By understanding the complexities of innate tumor drivers and adaptive host response within the tissue context, we can harmonize our understanding of targeted therapy approaches and immuno-oncology approaches , and make predictive assessments about a patients response to a given therapy.
His personal and professional mission is to advance medical diagnostics by solving complex biological assessments that capture a disease state and predict the efficacy of a drug for a specific patient application. While pathological approaches to tissue interpretation allow the exploration of these in-situ interactions, they are limited by their ability to deliver sufficient complexity and content to make clear associations with a higher content approach.